Results 61 to 70 of about 1,257,265 (356)
The insulin-like growth factor system and its receptors: A potential novel anticancer target
Biologics: Targets & Therapy, 2008 Colin R. Lindsay1, T R Jeffry Evans1,21Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 2University of Glasgow, CR-UK Beatson Laboratories, Garscube Estate, Glasgow, United KingdomAbstract: The current generation of novel anticancer ...
Colin R. Lindsay, T R Jeffry Evans
doaj
Hepatocyte and keratinocyte growth factors and their receptors in human lung emphysema
BMC Pulmonary Medicine, 2005 Background Hepatocyte and keratinocyte growth factors are key growth factors in the process of alveolar repair. We hypothesized that excessive alveolar destruction observed in lung emphysema involves impaired expression of hepatocyte and keratinocyte ...
Marchal Joëlle +8 more
doaj +1 more source
Identification of kinases activated by multiple pro-angiogenic growth factors
Frontiers in Pharmacology, 2023 Antiangiogenic therapy began as an effort to inhibit VEGF signaling, which was thought to be the sole factor driving tumor angiogenesis. It has become clear that there are more pro-angiogenic growth factors that can substitute for VEGF during tumor ...
Scott Gruver +3 more
doaj +1 more source
Developmental Disorders in Children Recently Diagnosed With Cancer
Pediatric Blood &Cancer, EarlyView.ABSTRACT Neurocognitive deficits in adult survivors of childhood cancer are well established, but less is known about developmental disorders (DD) arising shortly after cancer diagnosis. Using 2016–2019 linked Ohio cancer registry and Medicaid data, we compared DD among 324 children with cancer and 606,913 cancer‐free controls.
Jamie Shoag +5 more
wiley +1 more source
VEGF: An essential mediator of both angiogenesis and endochondral ossification [PDF]
, 2007 During bone growth, development, and remodeling, angiogenesis as well as osteogenesis are closely associated processes, sharing some essential mediators.
Dai, J, Rabie, ABM
core +1 more source
International Journal of Women's Health, 2020 Angela T Mlole, 1 James J Yahaya, 2 Emmanuel Othieno, 3 Sam Kalungi, 3 Andrew L Okwi 1 1Department of Pathology, Makerere College of Health Sciences (MaKCHS), Makerere University, Kampala, Uganda; 2Department of Biomedical Science, College of Health ...
Mlole AT +4 more
doaj
Epidermal Growth Factor Receptor Pathway [PDF]
Journal of Thoracic Oncology, 2010 The epidermal growth factor receptor (EGFR) pathway has provided a new therapeutic target in non-small cell lung cancer (NSCLC). Two EGFR tyrosine kinase inhibitors (TKIs) are being used globally as systemic treatment in advanced NSCLC. In addition, clinical observations with EGFR TKIS led to the discovery of EGFR activating mutations, which has ...
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background B‐acute lymphoblastic leukemia (B‐ALL) is the most common pediatric cancer, and while most children in high‐resource settings are cured, therapy carries risks for long‐term toxicities. Understanding parents’ concerns about these late effects is essential to guide anticipatory support and inform evolving therapeutic approaches ...
Kellee N. Parker +7 more
wiley +1 more source
Chemical regulators of epithelial plasticity reveal a nuclear receptor pathway controlling myofibroblast differentiation [PDF]
, 2016 Plasticity in epithelial tissues relates to processes of embryonic development, tissue fibrosis and cancer progression. Pharmacological modulation of epithelial transitions during disease progression may thus be clinically useful.
Bellomo, C +12 more
core +1 more source
Kidney Diseases, 2020 Background: Our recent studies demonstrated that both nintedanib, an FDA-approved quadruple kinase inhibitor, and gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, protect against obstructive kidney disease. It remains unknown whether they
Liu Feng +9 more
doaj +1 more source